Eli Lilly Jumps 6.3% on EU Nod for Cancer Drug, Medicare Inclusion
Eli Lilly (LLY) shares jumped 6.3% following a positive recommendation from the European Medicines Agency's committee for its cancer drug Jaypirca, and the inclusion of its weight-loss treatments in a new Medicare program.
Key Numbers
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 6.3% in the afternoon session after the European Medicines Agency's committee for human medicines backed its cancer drug, Jaypirca, and the company's popular weight-loss treatments were set for inclusion in a new Medicare program.
Details of the Action
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of Jaypirca (pirtobrutinib) for certain types of blood cancer. The decision follows clinical trials showing efficacy in patients who have failed prior therapies.
Additionally, Eli Lilly's weight-loss drugs, including Mounjaro and Zepbound, were included in a new Medicare program covering obesity medications, expanding access to these treatments.
Company's Position
Eli Lilly welcomed the positive CHMP opinion, calling it a significant step toward providing a new treatment option for patients with certain blood cancers. The company also expressed optimism about the Medicare inclusion, which could broaden patient access to its weight-loss drugs.
Precedents and Context
This development comes after Eli Lilly faced previous regulatory challenges in Europe and the U.S. The Medicare inclusion marks a shift in U.S. health coverage policy, as weight-loss drugs were previously excluded.
Potential Financial Impact
The European approval of Jaypirca is expected to boost the company's oncology revenues, while Medicare inclusion could significantly expand the patient base and drive sales. However, competition in the weight-loss drug market remains intense, particularly from Novo Nordisk.
Frequently Asked Questions
Found this useful? Share it